<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(1)</volume><submitter>Liu B</submitter><pubmed_abstract>Cisplatin (DDP) remains a cornerstone therapy for osteosarcoma (OS); however, pervasive resistance severely limits its clinical efficacy and worsens patient outcomes. Developing strategies to enhance the chemotherapeutic responsiveness of OS cells is therefore of critical importance. Here, we conducted a kinome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screen, coupled with transcriptome sequencing, to identify regulators of DDP sensitivity. This approach revealed protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1) as a key regulator of DDP sensitivity in OS. Subsequent analysis of patient-derived clinical specimens, along with in vitro functional assays, demonstrated that DDP treatment induces the activation of PKMYT1 in OS cells. Importantly, PKM</pubmed_abstract><journal>Signal transduction and targeted therapy</journal><pagination>165</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12092789</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma.</pubmed_title><pmcid>PMC12092789</pmcid><pubmed_authors>Jin X</pubmed_authors><pubmed_authors>Tu C</pubmed_authors><pubmed_authors>Xu R</pubmed_authors><pubmed_authors>Wan L</pubmed_authors><pubmed_authors>Fu Z</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Feng C</pubmed_authors><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>He S</pubmed_authors><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Liu B</pubmed_authors></additional><is_claimable>false</is_claimable><name>PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma.</name><description>Cisplatin (DDP) remains a cornerstone therapy for osteosarcoma (OS); however, pervasive resistance severely limits its clinical efficacy and worsens patient outcomes. Developing strategies to enhance the chemotherapeutic responsiveness of OS cells is therefore of critical importance. Here, we conducted a kinome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screen, coupled with transcriptome sequencing, to identify regulators of DDP sensitivity. This approach revealed protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1) as a key regulator of DDP sensitivity in OS. Subsequent analysis of patient-derived clinical specimens, along with in vitro functional assays, demonstrated that DDP treatment induces the activation of PKMYT1 in OS cells. Importantly, PKM</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-06-01T10:22:28.812Z</modification><creation>2026-04-08T11:22:55.009Z</creation></dates><accession>S-EPMC12092789</accession><cross_references><pubmed>40393983</pubmed><doi>10.1038/s41392-025-02250-7</doi></cross_references></HashMap>